British Journal of Cancer · 2014 · 49 citations · 31 references
MedicineMolecular BiologyOncologyCancer GeneticsMolecular OncologyOncogenesAssay ValidationBioanalytical Method ValidationCancer BiomarkersCancer Molecular DiagnosticsVolatile Organic CompoundsVolatile Substance AnalysisBiomarkersBreath Analysis MethodologyBreath Biomarker DetectionCancer Biomarker DetectionCell Type SpecificityLinear Discriminant AnalysisVolatile Organic Compound BiomarkersVolatile Organic Compound Detection
BACKGROUND: Volatile organic compounds (VOCs) are potential biomarkers for cancer detection in breath, but it is unclear if they reflect specific mutations. To test this, we have compared human bronchial epithelial cell (HBEC) cell lines carrying the KRAS(V12) mutation, knockdown of TP53 or both with parental HBEC cells. METHODS: VOC from headspace above cultured cells were collected by passive sampling and analysed by thermal desorption gas chromatography mass spectrometry (TD-GC-MS) or sensor array with discriminant factor analysis (DFA). RESULTS: In TD-GC-MS analysis, individual compounds had limited ability to discriminate between cell lines, but by applying DFA analysis combinations of 20 VOCs successfully discriminated between all cell types (accuracies 80-100%, with leave-one-out cross validation). Sensor array detection DFA demonstrated the ability to discriminate samples based on their cell type for all comparisons with accuracies varying between 77% and 93%. CONCLUSIONS: Our results demonstrate that minimal genetic changes in bronchial airway cells lead to detectable differences in levels of specific VOCs identified by TD-GC-MS or of patterns of VOCs identified by sensor array output. From the clinical aspect, these results suggest the possibility of breath analysis for detection of minimal genetic changes for earlier diagnosis or for genetic typing of lung cancers.
31
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein, Gordon B. Mills, Kenna Shaw et al. · Nature Genetics · 2013 · 9.5K citations · Full text
Systematic variation in gene expression patterns in human cancer cell lines
Douglas T. Ross, Uwe Scherf, Michael B. Eisen et al. · Nature Genetics · 2000 · 2.1K citations
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
William Pao, Theresa Y. Wang, Gregory J. Riely et al. · PLoS Medicine · 2005 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Diagnosing lung cancer in exhaled breath using gold nanoparticles
Gang Peng, Ulrike Tisch, Orna Adams et al. · Nature Nanotechnology · 2009 · 1.3K citations
Pharmacy, Bioengineering, Oncology +16
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takashi Takahashi, Marion M. Nau, Itsuo Chiba et al. · Science · 1989 · 1.2K citations